GB2607398.1 — Dermal Regeneration Scaffold
Skin that heals itself. From the ocean. No cold chain. No infection risk. Works where nothing else does. A lyophilised 3D porous scaffold that rehydrates on contact, conforms to wound geometry, and delivers intrinsic antimicrobial, anti-inflammatory, and pro-angiogenic activity — without exogenous growth factors, without refrigeration, without specialist clinical skill.
Every existing skin dressing stops at haemostasis or passive coverage. None are simultaneously haemostatic, antimicrobial, anti-inflammatory, and pro-angiogenic. The market has accepted this limitation. RAPIDSkin doesn't.
Existing products (QuikClot, Kaltostat, biological substitutes)
Passive dressings. Stop bleeding or cover the wound. No active biological contribution to healing.
No intrinsic antimicrobial activity. MRSA and drug-resistant organisms were endemic in Afghanistan and Iraq wound infections. Standard antibiotics are failing.
Cold chain dependent. Biological skin substitutes require refrigeration. Forward deployed positions and resource-limited settings cannot reliably maintain cold chains.
Fixed geometry. Sheet dressings don't conform to irregular wound topography — blast avulsion, deep burns, cavity wounds leave coverage gaps.
Infection or rejection risk. Biological substitutes carry donor-derived infection risk and immunogenic mismatch potential.
RAPIDSkin
Active biological scaffold. Alginate, fucoidan, phlorotannins, and holobiont antimicrobials each contribute distinct therapeutic mechanisms from the moment of application.
Intrinsic MRSA-active antimicrobial. Non-antibiotic mechanism via membrane disruption and anti-biofilm activity. No cross-resistance to any existing antibiotic class. Active from application.
Lyophilised. Ambient stable. Indefinite shelf life. No refrigeration. Reconstitutes on contact with wound exudate. Deployable anywhere.
Self-conforming 3D porous structure. Rehydrates and conforms to wound geometry — irregular, deep, and cavity wounds fully covered.
No donor material. No immunogenic risk. Entirely non-human origin. No blood-borne pathogen transmission. No rejection mechanism.
RAPIDSkin does not rely on a single therapeutic pathway. The four-component chemistry delivers six concurrent biological mechanisms from the moment of application — covering haemostasis, infection control, inflammation modulation, and tissue regeneration simultaneously.
Alginate — calcium ion exchange
Sargassum alginate activates the coagulation cascade via calcium ion exchange on contact with wound exudate. Wound moisture is simultaneously managed — not too dry to impede healing, not too wet to macerate surrounding tissue.
Phlorotannins — membrane disruption
Phlorotannins prevent initial bacterial adhesion — the optimal intervention point. Once a biofilm is established, it is orders of magnitude harder to eradicate. RAPIDSkin acts before the biofilm forms. Non-antibiotic. No cross-resistance.
Holobiont — secondary metabolites
Secondary metabolites from the sargassum-associated microbial community demonstrate documented MIC activity against MRSA and drug-resistant E. coli. Non-antibiotic mechanism. Unique to non-thermally-processed Bio-Farm harvest — cannot be synthesised or replicated.
Fucoidan + phlorotannins — NF-κB/MAPK/COX-2/Nrf2
Fucoidan and phlorotannins modulate the NF-κB, MAPK, COX-2, and Nrf2 pathways — the core drivers of wound inflammation. Reduces excessive inflammatory response without suppressing the healing cascade. Critical in blast and burn wounds where hyperinflammation impedes recovery.
Fucoidan — Akt/Nrf2/HIF-1α pathway
Fucoidan promotes new blood vessel formation via the Akt/Nrf2/HIF-1α pathway — active vascularisation of the wound bed during the evacuation window. New vasculature is the foundation of tissue regeneration. No exogenous growth factors required.
Fucoidan — type I collagen synthesis
Fucoidan promotes collagen type I deposition — the primary structural protein of dermis. Tissue regeneration begins during the evacuation window, not after. The scaffold provides the 3D architecture for organised collagen deposition and progressive dermal reconstruction.
RAPIDSkin addresses the wound types where existing products fail — irregular, contaminated, large-area, and resource-limited settings. Combat is the primary validation context. Civilian applications follow the same mechanism.
Combat — primary indication
IED and fragmentation injuries create irregular, contaminated, large-area skin loss. Self-conforming 3D structure covers complex geometry. Non-antibiotic MRSA activity addresses battlefield contamination. No cold chain for forward deployment.
Previous standard: Sheet dressings, wound VAC, staged grafting — coverage gaps, infection, delayed closure
Combat + civilian — major indication
Partial and full thickness burns. Anti-inflammatory mechanism reduces hyperinflammation that impedes burn wound healing. Pro-angiogenic activity supports perfusion into the wound bed. Ambient stable for pre-hospital and austere settings.
Previous standard: Biological dressings requiring cold chain, risk of donor-derived infection, limited availability in field
Civilian — NHS, care settings
Diabetic foot ulcers, pressure injuries, venous leg ulcers. Biofilm is the primary obstacle to chronic wound healing. Phlorotannin anti-biofilm activity addresses the root cause. Pro-angiogenic fucoidan restores perfusion to ischaemic wound beds.
Previous standard: Repeated debridement, antibiotic courses, passive dressings — symptom management without root cause treatment
Civilian — oncological, reconstructive
Post-resection defects, mastectomy, reconstructive surgery. Anti-biofilm protection reduces SSI risk — the most common post-operative complication. Scaffold architecture supports organised tissue ingrowth without secondary procedures.
Previous standard: Split-thickness grafting requiring donor site, systemic antibiotics, passive wound management
Humanitarian — global deployment
No cold chain, no specialist skill, ambient stable. Rehydrates on contact with wound exudate. Applicable in field hospitals, conflict zones, disaster response, and low-resource health systems where biological dressings are currently inaccessible.
Previous standard: Wound products requiring refrigeration or controlled conditions — simply unavailable in many settings
Combat + civilian — trauma, MVC
Road traffic injuries, industrial accidents, and combat wounds frequently involve environmental contamination. Anti-biofilm + holobiont MRSA activity prevents colonisation. Non-antibiotic mechanism preserves antibiotic options for systemic therapy.
Previous standard: Irrigation, antibiotic packing, delayed primary closure — increased infection rate, prolonged treatment
| Parameter | Specification |
|---|---|
| Form factor | Lyophilised 3D porous scaffold |
| Activation | Rehydrates on contact with wound exudate |
| Geometry | Self-conforming to irregular wound topography |
| Cold chain | Not required — ambient stable, indefinite shelf life |
| Feedstock | Arsenic-remediated pelagic sargassum, non-thermal processing |
| Active components | Alginate / Fucoidan / Phlorotannins / Holobiont antimicrobials |
| Antimicrobial | MRSA-active, drug-resistant E. coli — non-antibiotic mechanism |
| Growth factors | None required — intrinsic fucoidan activity |
| Donor material | None — non-human origin, zero immunogenic risk |
| Arsenic compliance | ICH Q3D pharmaceutical grade — inorganic arsenic limits achieved by extraction protocol |
| Regulatory pathway | Class III Medical Device (EU MDR) / 510(k) analogue (FDA) |
| Current TRL | 3 — patent filed, pre-clinical development |
Intellectual property
GB2607398.1
RAPIDSkin — Lyophilised Dermal Regeneration Scaffold from Non-Thermally-Processed Pelagic Sargassum
Lyophilised 3D porous scaffold formulation from arsenic-remediated pelagic sargassum retaining native fucoidan sulphation and living holobiont antimicrobial compound profile
Non-thermal extraction protocol — the enabling innovation distinguishing RAPIDSkin from all prior art scaffold products
Methods of use covering combat wound care, chronic wound management, surgical wound closure, and burn wound treatment
Pharmaceutical-grade sargassum supply chain protocol — three-stage arsenic management achieving ICH Q3D inorganic arsenic limits
Combination claim — four-component simultaneous haemostatic, anti-biofilm, pro-angiogenic, and tissue-regenerative activity from a single sargassum source. No prior art combination identified.
Dermal regeneration
RAPIDSkin
You are here
Research institutions · Defence procurement · NHS · Wound care industry
Full technical documentation, patent application GB2607398.1, pre-clinical evidence base, and supply chain model available under NDA to qualified partners. UKDI submission active. Technology Transfer Office pathway available.